Brachial Right Ventricle - Endomyocardial Biopsy
A Novel Method for Cardiac Allograft Monitoring:Transbrachial Right Ventricle Endomyocardial Biopsy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Tajinderpal Saraon
- Phone Number: 646-501-0119
- Email: Tajinderpal.Saraon@nyulangone.org
Study Contact Backup
- Name: Heart Failure Research Coordinators
- Phone Number: 646-501-0119
- Email: HFResearchcoordinators@nyulangone.org
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- NYU Langone Health
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient is 18 to 90 years old
- Patient is undergoing standard of care right heart catheterization with endomyocardial biopsy
- Patient has right arm brachial access available
- Patient is willing and able to provide written informed consent.
Exclusion Criteria:
- Peripherally inserted central catheter (PICC) line or arteriovenous (AV) fistula
- Severe untreated tricuspid valve regurgitation
- Female patients who are pregnant
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Participants undergoing Heart Catherization
Participants undergoing Heart Catherization and will complete a research survey focusing on the comfort and anxiety during procedure.
Participants will be followed for 18 months after enrollment.
For each clinically indicated Brachial RV-EMB Biopsy during the 18-month follow up period, data from biopsy and pre and post-procedure echocardiograms will be reviewed and recorded for research purposes.
A post-procedure questionnaire and post-discharge phone call will also take place after each procedure.
|
A questionnaire will be administered post-procedure to assess for pain and anxiety.
This questionnaire will be administered by study personnel delegated to administer questionnaires, namely the study coordinator or PI.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Satisfaction in Right endomyocardial biopsy via brachial access
Time Frame: Day 1 to Day 540
|
Assessed by patients self report of their experience when undergoing right endomyocardial biopsy via brachial access compared to transjugular and transfemoral right ventricle endomyocardial biopsy.
|
Day 1 to Day 540
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Tajinderpal Saraon, NYU Langone Health
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 21-01132
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.